New study aims to make diabetes drug safer for kidney patients

NCT ID NCT07325201

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 16 times

Summary

This study looks at how to safely use a diabetes medication (SGLT2 inhibitor) in people with type 1 diabetes and mild-to-moderate chronic kidney disease. Researchers will track blood sugar and ketone levels using continuous monitors to identify risk factors for diabetic ketoacidosis. About 80 adults will take the study drug and wear sensors for nine months, with regular check-ins. The goal is to create better reports that help patients and doctors prevent dangerous ketone buildup.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • International Diabetes Center

    Minneapolis, Minnesota, 55416, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.